Increasing Prevalence Of Inflammatory Bowel Diseases Fuels Growth In The Crohn'S Disease Treatment Market: Key Factor Driving The Growth In The Crohn's Disease (CD) Treatment Market

The Crohn's Disease (CD) Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Crohn's Disease (CD) Treatment Market Size During the Forecast Period?
The market for Crohn's Disease (CD) treatment has experienced considerable growth over the recent years. With a prediction to escalate from $11.76 billion in 2024 to $12.38 billion in 2025, it's exhibiting a compound annual growth rate (CAGR) of 5.3%. Factors such as an increased number of CD cases, heightened awareness about the disease, government programs, and lifestyle changes led to this progressive growth in the historical timeframe.

The market size for the treatment of Crohn's Disease (CD) is projected to witness robust expansion in the next few years. It is expected to reach a value of $15.06 billion in 2029, increasing at a Compound Annual Growth Rate (CAGR) of 5.0%. This growth during the forecast period can be associated with the escalating demand for combination therapies, a rise in the acceptance of biologics, and investments being made in research and development for the treatment of Crohn's Disease (CD). Significant trends for the forecast period encompass biologic drugs in development, pioneering products, state-of-the-art diagnostic tools, and the assimilation of biosimilars.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12902

What Are the High-Growth Segments in the Crohn's Disease (CD) Treatment Market?
The crohn's disease (CD) treatment market covered in this report is segmented -

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types
2) By Route of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:
1) By Antibiotics: Metronidazole, Ciprofloxacin, Rifaximin
2) By Amino Salicylates: Mesalamine, Sulfasalazine
3) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
4) By Immunomodulators: Azathioprine, Mercaptopurine, Methotrexate
5) By Other Drug Types: Biologic Therapies, Janus Kinase Inhibitors, Small Molecules

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp

What Key Drivers Are Expected to Influence Future Crohn's Disease (CD) Treatment Market Growth?
The escalating number of inflammatory bowel illnesses is set to speed up the expansion of the market for treating Crohn's disease (CD). Inflammatory bowel disease (IBD) refers to a collection of long-term inflammatory disorders that mainly impact the gastrointestinal (GI) tract. CD treatment aids in symptom alleviation, reduction of inflammation, promotion of remission, and enhancement of overall quality of life for those battling chronic inflammatory bowel disease. For example, in September 2023, the United States National Library of Medicine, a US-based health library, estimated that the incidence of IBD was about 30 per 100,000 person years in Canada in 2023, with predictions signifying a consistent rise of approximately 0.58% annually. As of 2023, Canada's IBD prevalence stood at roughly 825 per 100,000, with projections indicating that this could climb to 1.1% of the population by 2035. Consequently, the increasing rate of inflammatory bowel illnesses fuels the Crohn's disease (CD) treatment market. Amplifying the number of on-going clinical trials in treating Crohn's disease is expected to enhance market growth. The trials are essential for gauging the effectiveness and safety of these innovational therapies. Their success potentially leads to authorized approvals and the launching of new treatment alternatives for CD patients. This need for advanced and efficient CD treatments fuels the clinical trials. These trials are a result of patients and healthcare providers desiring improved outcomes with decreased side effects, which in turn motivates research and development initiatives. For instance, in September 2023, the University of California, a US-based public-funded land-grant research university, indicated that there are currently an impressive 17 on-going clinical trials at UCSF. These are specifically focusing on the use of vedolizumab and oral ozanimod and are intending to verify the long-term effectiveness of mirikizumab for juvenile patients who are suffering from Crohn's disease or ulcerative colitis. Therefore, the escalating number of clinical trials is anticipated to galvanize the growth of the Crohn's disease treatment market in the future.

Which Companies Hold the Largest Share Across Different Crohn's Disease (CD) Treatment Market Segments?
Major companies operating in the crohn's disease (cd) treatment market are Pfizer Inc., Johnson and Johnson Ltd., Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC.

What Trends Are Driving Growth in The Crohn's Disease (CD) Treatment Market?
Leading corporations in the Crohn's disease (CD) treatment sector are incorporating novel technologies, such as IBDSENSE, to maintain their stronghold in the market. For example, The IRR Chemistry Hub, headquartered in Scotland, rolled out IBDSENSE in March 2023. This technology is aimed at enhancing the diagnosis and monitoring of inflammatory bowel disease using non-invasive techniques, which include Crohn's disease. The initiative utilizes fluorescence-based technology for the measurement of Granzyme B (GzmB) enzyme activity in patient biosamples. This technology is designed to uplift patient experience and provide more options for treatment.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

What Are the Emerging Geographies for The Crohn's Disease (CD) Treatment Market Growth?
North America was the largest region in the Crohn's disease (CD) treatment market in 2024. The regions covered in Crohn's disease (CD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Crohn's Disease (CD) Treatment Market?
2. What is the CAGR expected in the Crohn's Disease (CD) Treatment Market?
3. What Are the Key Innovations Transforming the Crohn's Disease (CD) Treatment Industry?
4. Which Region Is Leading the Crohn's Disease (CD) Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.